Hemorrhagic and thrombotic events associated with generic substitution of warfarin in patients with atrial fibrillation: A retrospective analysis

Annals of Pharmacotherapy

Volumn 45, Issue 6, 2011, Pages 701-712

  Ghate, Sameer R ^a   Biskupiak, Joseph E ^a   Ye, Xiangyang ^a   Hagan, Michael ^a   Kwong, Winghan Jacqueline ^a   Fox, Eben S ^a   Brixner, Diana I ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

References

Indexed keywords

GENERIC DRUG; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; INSURANCE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK; RISK BENEFIT ANALYSIS;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BIOLOGICAL AVAILABILITY; DATABASES, FACTUAL; DRUGS, GENERIC; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK; THERAPEUTIC EQUIVALENCY; THROMBOSIS; WARFARIN;

EID: 79958855304     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P593     Document Type: Article

References (43)

1. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med 1990;323:1505-11. DOI 10.1056/NEJM199011293232201
2. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993;342:1255-62.
3. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996;348:633-8. DOI 10.1016/S0140-6736(96)03487-3
4. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991;18:349-55. DOI 10.1016/0735-1097(91)90585-W
5. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992;327:1406-12. DOI 10.1056/MEJM199211123272002.
6. Olsson SB, Halperin JL. Prevention of stroke in patients with atrial fibrillation. Semin Vasc Med 2005;5:285-92. DOI 10.1055/s-2005-916168
7. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-6. DOI 10.1056/NEJM199608223350802
8. Dolan G, Smith LA, Collins S, Plumb JM. Effect of setting, monitoring intensity and patient experience on anticoagulation control: a systematic review and meta-analysis of the literature. Curr Med Res Opin 2008;24: 1459-72. DOI 10.1185/030079908X297349
9. Jacobs LG. Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly. Cardiol Clin 2008;26:157-67, v. DOI 10.1016/j.ccl.2007.12.010
10. Mittmann N, Oh PI, Walker SE, Bartle WR. Warfarin in the secondary prevention of thromboembolism in atrial fibrillation: impact of bioavailability on costs and outcomes. Pharmacoeconomics 2004;22:671-83.
11. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165: 1095-106. DOI 10.1001/archinte.165.10.1095
12. Orange Book: approved drug products with therapeutic equivalence evaluations. US Government Publications, Washington, DC, 2010.
13. Approved drug products and legal requirements. 18th ed. Rockville, MD: The United States Pharmacopeia, 1998.
14. FDA position on product selection for 'narrow therapeutic index' drugs. Am J Health Syst Pharm 1997;54:1630-2.
15. Meredith PA. Generic drugs. Therapeutic equivalence. Drug Saf 1996; 15:233-42.
16. Pope ND. Generic substitution of narrow therapeutic index drugs. US Pharmacist 2009;34(6):12-9.
17. Handler J NT, Rush S, Pham NT. A blinded, randomized crossover study comparing the efficacy and safety of generic warfarin sodium to Coumadin. Prevent Cardiol 1998;4:13-20.
18. Milligan PE, Banet GA, Waterman AD, Gatchel SK, Gage BF. Substitution of generic warfarin for Coumadin in an HMO setting. Ann Pharmacother 2002;36:764-8. DOI 10.1345/aph.1A327
19. Neutel JM, Smith DH. Hypertension: where have we gone wrong and how can we fix it? Am J Hypertens 1998;11:150S-7S. DOI 10.1016/S0895-7061(98)00192-7
20. Pereira JA, Holbrook AM, Dolovich L, et al. Are brand-name and generic warfarin interchangeable? Multiple n-of-1 randomized, crossover trials. Ann Pharmacother 2005;39:1188-93. DOI 10.1345/aph.1G003
21. Weibert RT, Yeager BF, Wittkowsky AK, et al. A randomized, crossover comparison of warfarin products in the treatment of chronic atrial fibrillation. Ann Pharmacother 2000;34:981-8. DOI 10.1345/aph.10068
22. Swenson CN, Fundak G. Observational cohort study of switching warfarin sodium products in a managed care organization. Am J Health Syst Pharm 2000;57:452-5.
23. Halkin H, Shapiro J, Kurnik D, Loebstein R, Shalev V, Kokia E. Increased warfarin doses and decreased international normalized ratio response after nationwide generic switching. Clin Pharmacol Ther 2003; 74:215-21. DOI 10.1016/S0009-9236(03)00166-8
24. Witt DM, Tillman DJ, Evans CM, Plotkin TV, Sadler MA. Evaluation of the clinical and economic impact of a brand name-to-generic warfarin sodium conversion program. Pharmacotherapy 2003;23:360-8.
25. Kim MH, Lin J, Hussein M, Kreilick C, Battleman D. Cost of atrial fibrillation in United States managed care organizations. Adv Ther 2009; 26:847-57. DOI 10.1007/s12325-009-0066-x
26. Naccarelli GV, Johnston SS, Lin J, Patel PP, Schulman KL. Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States. Clin Cardiol 2010;33:270-9. DOI 10.1002/clc.20759
27. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009;104:1534-9. DOI 10.1016/j.amjcard.2009.07.022
28. Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF. Lifetime cost of stroke in the United States. Stroke 1996;27:1459-66.
29. Zimetbaum PJ, Thosani A, Yu HT, et al. Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? Am J Med 2010; 123:446-53. DOI 10.1016/j.amjmed.2009.11.015
30. Drug topics red book. Montvale, NJ: Thomson Reuters, 2008.
31. Schauer DP, Moomaw CJ, Wess M, Webb T, Eckman MH. Psychosocial risk factors for adverse outcomes in patients with nonvalvular atrial fibrillation receiving warfarin. J Gen Intern Med 2005;20:1114-9. DOI 10.1111/j.1525-1497.2005.0242.x
32. Edelsberg J, Hagiwara M, Taneja C, Oster G. Risk of venous thromboembolism among hospitalized medically ill patients. Am J Health Syst Pharm 2006;63(suppl):S16-22. DOI 10.2146/ajhp060389
33. White RH, Beyth RJ, Zhou H, Romano PS. Major bleeding after hospitalization for deep-venous thrombosis. Am J Med 1999;107:414-24. DOI 10.1016/S0002-9343(99)00267-3
34. Walker AM, Bennett D. Epidemiology and outcomes in patients with atrial fibrillation in the United States. Heart Rhythm 2008;5:1365-72. DOI 10.1016/j.hrthm.2008.07.014
35. Karni A, Holtzman R, Bass T, et al. Traumatic head injury in the anticoagulated elderly patient: a lethal combination. Am Surg 2001;67:1098-100.
36. D'Hoore W, Sicotte C, Tilquin C. Risk adjustment in outcome assessment: the Charlson comorbidity index. Methods Inf Med 1993;32:382-7.
37. van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002;288:2441-8. DOI 10.1001/jama.288.19.2441
38. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003;290:2685-92. DOI 10.1001/jama.290.20.2685290
39. 201 KAR 2:116. Drug products with therapeutic problems.www.lrc.state.ky.us/kar/201/002/116.htm (accessed 2010 Apr 20).
40. South Carolina Code of Laws (unannotated). www.scstatehouse.net/code/t39c024.htm (accessed 2010 Apr 20).
41. Commonwealth of Pennsylvania generic drug equivalency/substitution laws & regulations. http://ecapps.health.state.pa.us/pdf/ddc/generic33.ps.pdf (accessed 2010 Apr 20).
42. North Carolina Board of Pharmacy. Pharmacy rules, statutes, and board policies. www.ncbop.org/LawRules/StatutesMay2007.pdf (accessed 2010 Apr 20).
43. Rose AJ, Ozonoff A, Grant RW, Henault LE, Hylek EM. Epidemiology of subtherapeutic anticoagulation in the United States. Circ Cardiovasc Qual Outcomes 2009;2:591-7. DOI 10.1161/CIRCOUTCOMES.109.862763